Pimavanserin
Phase 3Terminated 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Adjunctive Treatment of Major Depressive Disorder
Conditions
Adjunctive Treatment of Major Depressive Disorder
Trial Timeline
Jun 6, 2019 → Feb 22, 2021
NCT ID
NCT04000009About Pimavanserin
Pimavanserin is a phase 3 stage product being developed by Acadia Pharmaceuticals for Adjunctive Treatment of Major Depressive Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT04000009. Target conditions include Adjunctive Treatment of Major Depressive Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05796167 | Phase 1 | Withdrawn |
| NCT05357612 | Approved | Recruiting |
| NCT04809116 | Approved | Withdrawn |
| NCT05555615 | Phase 2/3 | Terminated |
| NCT04292223 | Approved | Completed |
| NCT04000009 | Phase 3 | Terminated |
| NCT03623321 | Phase 3 | Completed |
| NCT03482882 | Phase 2 | Completed |
| NCT03118947 | Phase 2 | Completed |
| NCT03121586 | Phase 3 | Terminated |
| NCT03018340 | Phase 2 | Completed |
Competing Products
2 competing products in Adjunctive Treatment of Major Depressive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pimavanserin | Acadia Pharmaceuticals | Phase 2 | 47 |
| Pimavanserin + Placebo | Acadia Pharmaceuticals | Phase 3 | 72 |